Radionuclide Therapy (inbunden)
Fler böcker inom
Inbunden (Hardback)
Antal sidor
1st ed. 2022
Springer Nature Switzerland AG
Beki¿, Recep (ed.), Bozkurt, Murat Fani (ed.), Polack, Berna (ed.)
101 Illustrations, color; 21 Illustrations, black and white; XXIII, 387 p. 122 illus., 101 illus. in
256 x 180 x 26 mm
1044 g
Antal komponenter
1 Hardback
Radionuclide Therapy (inbunden)

Radionuclide Therapy

Inbunden,  Turkiska, 2022-08-02
  • Skickas från oss inom 3-6 vardagar.
  • Fri frakt över 249 kr för privatkunder i Sverige.
Radionuclide Therapy Kan levereras innan julafton
The main purpose of this book is to create a reference for the indications, contraindications, patient selection, treatment practice, treatment side effect management, and follow-up of radionuclide treatments. Besides standard methods such as surgery, chemotherapy, radiotherapy, and hormone therapy, newly developed biological treatments, targeted treatments, personalized treatments, external beam radiotherapy, and targeted radionuclide treatments have begun to take their place in professional practice. Nuclear medicine, in addition to its role as a tracer of cancer, also assumes the role of treating with radioactive molecules directed to the cancer it traces. These traceable next-generation radionuclide treatments, whose efficacy and reliability have been proven and where diagnosis, treatment, and follow-up are carried out together, are increasingly included in oncology practice together with the new developed radiopharmaceuticals, ensuring a high rate of damage to cancer cells while protecting the surrounding normal tissues. Molecular cancer treatment will become more effective with individualized next-generation traceable radionuclide treatments, which will be shaped by genetic studies in the future. Radionuclide treatments for many cancer types and benign diseases are presented by experienced nuclear medicine experts in the light of their own experience and case studies, while systemic treatments in common cancer types and side effect management of these treatments are summarized by medical oncologists. This book will be of interest to nuclear medicine physicians as well as oncologists.
Visa hela texten

Passar bra ihop

  1. Radionuclide Therapy
  2. +
  3. Salvestrol

De som köpt den här boken har ofta också köpt Salvestrol (häftad).

Köp båda 2 för 2455 kr


Har du läst boken? Sätt ditt betyg »

Övrig information

Prof. Dr. Recep Beki graduated from Sivas High School in 1985. Between 1985-1991, he studied Medicine at Cumhuriyet University Faculty of Medicine. He graduated from the Faculty of Medicine in 1991 and worked as a general practitioner at Ankara Oncology Hospital between 1991-1996. He attended courses and seminars in the field of oncology. In 1996, he started as an assistant in Nuclear Medicine at Dokuz Eylul University Faculty of Medicine. He became a nuclear medicine specialist in 2000, assistant professor in 2002, associate professor in 2006, and professor in 2011. He is currently working as a faculty member at Dokuz Eyll University Faculty of Medicine, Department of Nuclear Medicine. He was appointed as the head of Nuclear Medicine Department at Dokuz Eylul University Faculty of Medicine, and as an assistant chief physician. He published 71 articles in national and international journals and 157 notifications in national and international scientific meetings. He is a chapter author in a book and chief editor in a book. He teaches at the medical faculty and health vocational high school. He is a member of professional scientific organizations and works actively in working groups in these organizations. Prof. Dr. Berna Polack, a nuclear medicine specialist by training, has been working in molecular imaging and radioligand therapies since 1991. She became a nuclear medicine professor in 2005 at Dokuz Eylul University, Izmir, Turkey. Dr. Polack has a European Nuclear Medicine Fellowship Board. During her carrier, she also worked as research professor and visiting professor positions at the Pittsburg University of Medical Center (July 2003- October 2004), Cornell University Weil Medical College Radiology Department (July 2013-December 2014), and Columbia University Medical Center Radiology Department (September 2016- May 2017). During her positions, she presented lectures in radiology residency training programs and attended research studies as well as imaging evaluation and multidisciplinary oncology tumor boards. She is the first or co-author of multiple publications published in SCI and SCI-expanded medical journals and two international nuclear medicine textbook chapters. She is the editor of a book entitled PET/CT in Oncology. Dr. Polack presented numerous congress presentations in national and international congresses. Additionally, she was awarded multiple national and international nuclear medicine research awards. She served as a director of the Turkish Nuclear Medicine Association Oncology Task Group. After she retired from Dokuz Eylul University in 2017, Dr. Polack joined the pharmaceutical industry, focusing on innovative molecular imaging and radioligand therapies. She is currently working as Medical Director, Prostate Cancer RLT at Novartis. Her main areas of focus are nuclear oncology, innovative molecular imaging, and radioligand therapies. Prof. Dr Murat Fani Bozkurt completed his medical training at Hacettepe University Medical School in 1997. He had his residency training at Department of Nuclear Medicine, Hacettepe University from 1997 to 2003. Dr Bozkurt completed a reseach fellowship program on oncological PET imaging at University of Pennsylvania PET Center in Philadelphia, USA in 2003. He began to work as a staff at Department of Nuclear Medicine, Hacettepe University Faculty of Medicine in 2005. Dr Bozkurt completed a visiting scientist program on Cardiac PET imaging at Nuclear Cardiology Department at Harvard University Brigham and Womens Hospital in 2009. Dr Bozkurt had his associate professorship degree in 2010. He was also certified by European Board of Nuclear Medicine in the same year. He was assigned as a member of Oncology Task Group of European Association of Nuclear Medicine (EANM) in 2010 and consequently functioned as senior advisor in the years 2014-2016. He undertook chief chair position for European Multimodality Imaging and Therapy (ESMIT)


Part-1: Basic Information 1. Basic properties and preparation of radiopharmaceuticals used in radionuclide therapy2. Physical Bases of Radionuclide Therapy (Biological Effects and Properties of Particle Radiation)3. Fundamentals of radiation safety and dosimetric approach in radionuclide therapy applicationsPart-2: Clinical Information: Thyroid Diseases 4. Radionuclide Therapy in Benign Thyroid Diseases: Nodular Goiter Disease5. Radionuclide Therapy in Benign Thyroid Diseases: Graves' Disease 6. Radionuclide Therapy in Malignant Thyroid Diseases: Differentiated Thyroid Cancer7. Radionuclide Therapy in Malignant Thyroid Diseases: Medullary Thyroid Cancer 8. Systemic Treatments and related side effects in Thyroid Cancer Part-2: Clinical Information: Neuroendocrine Tumors 9. Radionuclide Therapy in Neuroendocrine Tumors10. Systemic Treatments and related side effects in Neuroendocrine Tumors Part-4: Clinical Information: Neuroectodermal Tumors 11. Radionuclide Therapy in Neuroectodermal Tumors12. Systemic Treatments and related side effects in Neuroectodermal Tumors Part-5: Clinical Information: Liver Tumors 13. Radionuclide Therapy in Liver Tumors14. Systemic Treatments and related side effects in Liver TumorsPart-6: Clinical Information: Prostate Cancer 15. Radionuclide Therapy in Prostate Cancer16. Systemic Treatments and related side effects in Prostate Cancer17. Radionuclide Therapy in Joint Diseases: Radiosynovectomy18. Radionuclide Pain Palliation TherapyPart-7: Clinical Information: Bone and Joint Diseases 19. Radionuclide Therapy with Alpha Emitting Agents in Bone Metastases Part-8: Clinical Information: Lymphoproliferative Diseases 20. Radionuclide Therapy in Lymphoproliferative Diseases Part-9: Radioimmunotherapy 21. Basics and clinical applications of radioimmunotherapy Part-10: Intracavitary Radionuclide Therapy 22. Intracavitary radionuclide applications